Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | OGT | O15294 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4552072 | 0.82 | PTGS2 (0.49) | PTGS2 | |
| SCHEMBL4551905 | 0.82 | PTGS2 (0.47) | LMNAPTGS2 | |
| SCHEMBL4553604 | 0.78 | CDK5 (0.46) | MAPTTP53PTGS2POLBRXFP1 | |
| SCHEMBL27629489 | 0.77 | PGR (0.52) | LMNAMAPTOGTTP53POLB | |
| SCHEMBL4553299 | 0.76 | MAPT (0.52) | LMNAMAPTOGTTP53POLB | |
| SCHEMBL1055214 | 0.75 | GRIN2D (0.53) | LMNAMAPTOGTTP53POLB | |
| SCHEMBL4553365 | 0.74 | MAPT (0.50) | LMNAMAPTOGTTP53POLB | |
| SCHEMBL5534592 | 0.73 | PGR (0.40) | LMNAMAPTOGTTP53POLB | |
| SCHEMBL4553222 | 0.73 | GRIN2D (0.57) | LMNAMAPTOGTTP53 | |
| SCHEMBL4553042 | 0.72 | TNKS2 (0.47) | LMNAMAPTOGTTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | LMNA 1957/4885MAPT 575/4885OGT 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.